about
Diverse mechanisms of antiepileptic drugs in the development pipelineModulating Behavior in C. elegans Using Electroshock and Antiepileptic DrugsFlupirtine: Clinical pharmacologyLack of effect of ezogabine/retigabine on the pharmacokinetics of digoxin in healthy individuals: results from a drug-drug interaction study.Voltage-gated potassium channels at the crossroads of neuronal function, ischemic tolerance, and neurodegeneration.Expression and function of the K+ channel KCNQ genes in human arteries.Flupirtine: pharmacology and clinical applications of a nonopioid analgesic and potentially neuroprotective compound.Activation of vascular KCNQ (Kv7) potassium channels reverses spasmogen-induced constrictor responses in rat basilar artery.Clinical utility of adjunctive retigabine in partial onset seizures in adults.Perspectives on treatment options for mesial temporal lobe epilepsy with hippocampal sclerosis.Atomic basis for therapeutic activation of neuronal potassium channels.Antidystonic effects of Kv7 (KCNQ) channel openers in the dt sz mutant, an animal model of primary paroxysmal dystoniaEpilepsy: a review of selected clinical syndromes and advances in basic science.Vascular KCNQ (Kv7) potassium channels as common signaling intermediates and therapeutic targets in cerebral vasospasm.A study of subunit selectivity, mechanism and site of action of the delta selective compound 2 (DS2) at human recombinant and rodent native GABA(A) receptors.Kv7 channels: interaction with dopaminergic and serotonergic neurotransmission in the CNS.Activation of neuronal Kv7/KCNQ/M-channels by the opener QO58-lysine and its anti-nociceptive effects on inflammatory pain in rodents.Action potential initiation and propagation: upstream influences on neurotransmissionAdolescent Clinical Development of Ezogabine/Retigabine as Adjunctive Therapy for Partial-Onset Seizures: Pharmacokinetics and Tolerability.Voltage-gated potassium channels as therapeutic targets.Epilepsy-Associated KCNQ2 Channels Regulate Multiple Intrinsic Properties of Layer 2/3 Pyramidal NeuronsNew and investigational antiepileptic drugs.Pharmacological modulation of voltage-gated potassium channels as a therapeutic strategy.Ion channel blockers for the treatment of neuropathic pain.Ezogabine: an evaluation of its efficacy and safety as adjunctive therapy for partial-onset seizures in adults.Coexpression and activation of TRPV1 suppress the activity of the KCNQ2/3 channel.Activation of peripheral KCNQ channels attenuates inflammatory pain.Desensitization of chemical activation by auxiliary subunits: convergence of molecular determinants critical for augmenting KCNQ1 potassium channels.KCNQ modulators reveal a key role for KCNQ potassium channels in regulating the tone of rat pulmonary artery smooth muscle.A schizophrenia-linked mutation in PIP5K2A fails to activate neuronal M channels.Bioequivalence study of two formulations of flupirtine maleate capsules in healthy male Chinese volunteers under fasting and fed conditions.Discovery of Aromatic Carbamates that Confer Neuroprotective Activity by Enhancing Autophagy and Inducing the Anti-Apoptotic Protein B-Cell Lymphoma 2 (Bcl-2).Role of KCNQ2 channels in orofacial cold sensitivity: KCNQ2 upregulation in trigeminal ganglion neurons after infraorbital nerve chronic constrictive injury.The pharmacological effect of positive KCNQ (Kv7) modulators on dopamine release from striatal slices.Identification and validation of midbrain Kcnq4 regulation of heavy alcohol consumption in rodents.Ancient and modern anticonvulsants act synergistically in a KCNQ potassium channel binding pocket
P2860
Q24675330-D89FE35B-9CAC-41FE-B67B-725E05DFC911Q27321178-6E73B2C8-4EBF-488D-B357-7E11805C598BQ34272694-1EE39165-BFC0-44B8-BB83-CAADCDB6C0A2Q34386899-3D649673-319D-48AB-B5F6-28BEE226BD14Q34390785-9A6B8BFC-EFD4-4A13-A452-387906DEE1F8Q34449702-450CA0A1-ED5D-44D6-A12B-B7F147C9C49EQ34985534-84A9930F-E26A-4C0A-A83C-24D19FA92EB3Q35216454-564209C5-C753-4E20-B589-BFEA7A4B2D96Q35717049-8EDFE1BC-DCC7-492B-85AD-2952F744C0B7Q35761335-EA9233F0-FAFB-4154-918C-6CB81690CF02Q36033788-782E8685-9F8D-49E0-AB12-A6A19764CCE3Q36054393-D2700CE4-A351-4971-872F-F8FC4227F923Q36377765-05BF0803-8937-4BD2-BCCE-65D55D705D46Q36514114-4A2B2358-4BEA-4427-90E9-92064F68C719Q36675803-9F93CB4E-FB8C-401B-979D-390E5902AC73Q37049822-98741E6B-94BF-407C-8A91-DC57D054789BQ37151594-C54DFE3B-B54C-452E-AE50-CC8F51345324Q37160148-293F068E-0724-4A6F-8519-8F23A0C902E1Q37406223-44E5E9BD-DB1B-4BAB-972D-21CF04643D6CQ37464784-BBEF9B1F-4343-45CC-BE39-6E07327426B3Q37592170-2F85D9C5-9EDA-4031-9646-F0BF505B94A0Q37638688-2BF5F478-5056-4BB8-A7FD-0D4294CF2C57Q37781356-29472092-C285-45C8-ADDC-570E91E18A3CQ37855929-3A972B31-BE48-4D88-B7A9-A3EB3E31D68EQ38044694-0110E10F-9253-4AB9-8BDB-DA76B30B155FQ38371584-4C051C65-9355-4B3F-858E-0EDE53F2E425Q41943120-2C8BD0FC-ACF8-40C9-AE5F-DF3A8EF15F4BQ41988367-6887FE01-8474-4354-AA27-F591EB37AA22Q42110971-287177AE-2569-485B-941C-1E8624D0B5D3Q42437288-05F1DCC0-EB14-4058-A253-4851BBE4F43AQ47111029-20D4E9D6-623C-4333-AED5-40772961A35DQ47432782-077506D9-452C-41BA-8360-C580E91BF4FAQ50043730-12030877-9779-47AF-80DA-544E97153279Q51566365-F31D4CE0-4628-4CBB-B49F-284D56CEE9D3Q54220815-2E9B6D06-DEF4-4478-9BC2-8CE3E5EC75ACQ57921983-ACB5371B-A8F0-4A30-BDBA-78848BAC7760
P2860
description
2005 nî lūn-bûn
@nan
2005 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Retigabine: chemical synthesis to clinical application.
@ast
Retigabine: chemical synthesis to clinical application.
@en
Retigabine: chemical synthesis to clinical application.
@nl
type
label
Retigabine: chemical synthesis to clinical application.
@ast
Retigabine: chemical synthesis to clinical application.
@en
Retigabine: chemical synthesis to clinical application.
@nl
prefLabel
Retigabine: chemical synthesis to clinical application.
@ast
Retigabine: chemical synthesis to clinical application.
@en
Retigabine: chemical synthesis to clinical application.
@nl
P2093
P1476
Retigabine: chemical synthesis to clinical application
@en
P2093
G Blackburn-Munro
J D Mikkelsen
R E Blackburn-Munro
W Dalby-Brown
P356
10.1111/J.1527-3458.2005.TB00033.X
P577
2005-01-01T00:00:00Z